Results 111 to 120 of about 700,247 (353)

Exploring the Endothelin-1 pathway in chronic thromboembolic pulmonary hypertension microvasculopathy

open access: yesScientific Reports
Targeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic ...
Benchenouf Feriel   +16 more
doaj   +1 more source

Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension

open access: yesJournal of Cardiovascular Development and Disease
Background: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear.
Steven Hopkins   +8 more
doaj   +1 more source

Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial

open access: yesAdvanced Science, EarlyView.
Refractory status epilepticus (RSE) is a life‐threatening neurological emergency with high rates of death and long‐term disability, but treatments for it are often based on limited evidence. RSE is now understood to involve neuroinflammation, which has led to the exploration of anti‐inflammatory and immunomodulatory agents like Tocilizumab. Traditional
Shanika Samarasekera   +12 more
wiley   +1 more source

Patient engagement and self-management in pulmonary arterial hypertension

open access: yesEuropean Respiratory Review, 2016
Improved care in pulmonary arterial hypertension has led to increased longevity for patients, with a paralleled evolution in the nature of their needs.
Jytte Graarup   +2 more
doaj   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

open access: yes, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A   +9 more
core   +1 more source

Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
Soluble GRP78 (sGRP78) is identified as a novel tumor‐derived soluble factor that induces regulatory T cells (Treg). sGRP78 serves as an excellent serological biomarker for predicting the efficacy of neoadjuvant therapy in breast cancer patients. sGRP78 specifically binds to B cells, inducing the expression of IL‐10 and PD‐L1, thereby promoting Treg ...
Zhenghao Wu   +10 more
wiley   +1 more source

Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. [PDF]

open access: yes, 2015
Pulmonary arterial hypertension (PAH) can be idiopathic or secondary to autoimmune diseases, and it represents one of the most threatening complications of systemic sclerosis (SSc).
Alessandri, Cristiano   +9 more
core   +2 more sources

PIEZO Force Sensing in Vascular Biology: An Explosion of New Knowledge, Concepts and Opportunity

open access: yesAdvanced Science, EarlyView.
Knowledge of the remarkable mechanical force sensing and electrically transducing PIEZO1 and PIEZO2 channels is discussed across vascular biology and its cell types from the embryonic to adult stages in health, disease and old age. How the channels work, relate to other factors and signal for tissue responses to mechanical forces is debated.
David J Beech
wiley   +1 more source

Home - About - Disclaimer - Privacy